Advertisement

Topics

Top Investors Back British Biotech’s Series B to Fight Pulmonary Infections

05:59 EDT 20 Mar 2017 | Labiotech.eu

Pulmocide has raised €28.25M ($30.4M) in Series B that will let the company progress its candidates for respiratory infections through early clinical trials.  Pulmocide, based in London, is developing inhaled drugs to treat respiratory syncytial virus (RSV) and Aspergillus infections in ...

This awesome article Top Investors Back British Biotech’s Series B to Fight Pulmonary Infections appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)

Original Article: Top Investors Back British Biotech’s Series B to Fight Pulmonary Infections

NEXT ARTICLE

More From BioPortfolio on "Top Investors Back British Biotech’s Series B to Fight Pulmonary Infections"

Quick Search
Advertisement
 

Relevant Topics

Respiratory
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...